

Marco Daperno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2498868/publications.pdf>

Version: 2024-02-01

73
papers

5,742
citations

172207

29
h-index

82410

72
g-index

76
all docs

76
docs citations

76
times ranked

6254
citing authors

#	ARTICLE	IF	CITATIONS
1	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 3-25.	0.6	1,547
2	Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 505-512.	0.5	1,326
3	European evidence based consensus for endoscopy in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 982-1018.	0.6	679
4	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	2.4	316
5	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 484-498.	0.6	93
6	Neuropeptide S Receptor 1 Gene Polymorphism Is Associated With Susceptibility to Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2007, 133, 808-817.	0.6	87
7	Infliximab and the risk of latent viruses reactivation in active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 896-902.	0.9	84
8	Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2014, 46, 969-973.	0.4	78
9	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1119-1125.	6.1	74
10	Abdominal bowel ultrasound can predict the risk of surgery in Crohn's disease: Proposal of an ultrasonographic score. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 585-593.	0.6	72
11	Adalimumab in active ulcerative colitis: A real-life observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.4	72
12	Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. <i>Digestive and Liver Disease</i> , 2010, 42, 175-178.	0.4	70
13	Pregnancy before and after the diagnosis of inflammatory bowel diseases: Retrospective case-control study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 542-549.	1.4	68
14	Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1118-1127.e5.	0.5	62
15	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 852-858.	0.6	54
16	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, 604-617.	0.4	47
17	EUS diagnosis and simultaneous endoscopic retrograde cholangiography treatment of common bile duct stones by using an oblique-viewing echoendoscope. <i>Gastrointestinal Endoscopy</i> , 2006, 63, 479-484.	0.5	44
18	Advances in biologic therapy for ulcerative colitis and Crohn's disease. <i>Current Gastroenterology Reports</i> , 2006, 8, 506-512.	1.1	43

#	ARTICLE	IF	CITATIONS
19	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
20	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 294-306.	3.7	42
21	Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 428-436.	1.9	41
22	Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 758-766.	0.9	41
23	An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 1558-1569.e8.	0.6	41
24	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.4	39
25	CARD15 Gene Variants and Risk of Reoperation in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2009, 104, 2483-2491.	0.2	37
26	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
27	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.4	34
28	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 450-459.	0.9	33
29	Interassay and Interobserver Variability in the Detection of Anti-neutrophil Cytoplasmic Antibodies in Patients with Ulcerative Colitis. <i>Clinical Chemistry</i> , 2004, 50, 1422-1425.	1.5	32
30	Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps. <i>Endoscopy</i> , 2018, 50, 779-789.	1.0	32
31	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 913-924.	0.6	30
32	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1642-1652.	0.6	27
33	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. <i>Journal of Crohn's and Colitis</i> , 2016, 11, j11w181.	0.6	27
34	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , 2019, 51, 972-977.	0.4	25
35	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IBD LIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	1.9	25
36	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018, 50, 653-660.	0.4	22

#	ARTICLE	IF	CITATIONS
37	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
38	The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 327-330.	0.6	18
39	Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2016, 48, 138-143.	0.4	18
40	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). <i>Gut</i> , 2022, 71, 1078-1087.	6.1	18
41	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. <i>Gut</i> , 2021, 70, gutjnl-2020-320690.	6.1	17
42	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	1.3	16
43	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	1.6	16
44	PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2022, 10, 147-159.	1.6	16
45	The diagnosis of inflammatory bowel disease is often unsupported in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 20-23.	0.4	12
46	Eosinophilia associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. <i>Apmis</i> , 2017, 125, 179-183.	0.9	12
47	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-9.	0.7	12
48	Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohn's Disease: Tipping the Balance. <i>Current Medicinal Chemistry</i> , 2007, 14, 1489-1497.	1.2	11
49	Treatment of tracheoesophageal fistula in a child by using an endoscopic suturing device. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 932-935.	0.5	11
50	Identification of a new WASP and FKBP-like (WAFL) protein in inflammatory bowel disease: a potential marker gene for ulcerative colitis. <i>International Journal of Colorectal Disease</i> , 2008, 23, 921-930.	1.0	11
51	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	1.4	11
52	Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 174-182.e2.	0.5	11
53	Lower gastrointestinal bleeding in Crohn's disease: How (un-)common is it and how to tackle it?. <i>Digestive and Liver Disease</i> , 2012, 44, 721-722.	0.4	10
54	Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. <i>United European Gastroenterology Journal</i> , 2021, 9, 102-109.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Topical Therapy in Ulcerative Colitis: Always a Bridesmaid but Never a Bride?. <i>Gastroenterology</i> , 2015, 148, 701-704.	0.6	7
56	Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. <i>Digestive and Liver Disease</i> , 2017, 49, 997-1002.	0.4	7
57	Asymptotic distributions of kappa statistics and their differences with many raters, many rating categories and two conditions. <i>Biometrical Journal</i> , 2018, 60, 146-154.	0.6	7
58	Predictivity of early and late assessment for post-surgical recurrence of Crohn's disease: Data from a single-center retrospective series. <i>Digestive and Liver Disease</i> , 2021, 53, 987-995.	0.4	7
59	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2019, 51, 212-217.	0.4	6
60	Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1011-1019.	0.6	6
61	Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation. <i>Digestive and Liver Disease</i> , 2019, 51, 1117-1122.	0.4	5
62	Genotype-phenotype relationship in inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , 2000, 11, 204-209.	1.0	4
63	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , 2019, 1, 93-99.	0.3	3
64	Has the Removing of the Mesentery during Ileo-Colic Resection an Impact on Post-Operative Complications and Recurrence in Crohn's Disease? Results from the Resection of the Mesentery Study (Remedy). <i>Journal of Clinical Medicine</i> , 2022, 11, 1961.	1.0	3
65	Advances in medical therapy for Crohn's disease. <i>Current Gastroenterology Reports</i> , 2002, 4, 506-512.	1.1	2
66	Post-operative Recurrence of Crohn's Disease: There Is More to It than Meets the Eye. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 999-1000.	0.6	2
67	Risk factors of SARS-CoV-2 seroprevalence among hospital employees in Italy: a single-centre study. <i>Internal Medicine Journal</i> , 2021, 51, 1049-1059.	0.5	2
68	Who are the patients with Crohn's disease unsuitable to receive an anti-TNF± therapy? Results from a survey of Italian physicians and literature review. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1082-1090.	0.8	2
69	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	2
70	Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD). <i>Digestive and Liver Disease</i> , 2020, 52, 928-930.	0.4	1
71	Scoring Endoscopy in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 73, 48-53.	0.9	1
72	Rescue immune suppression for severe colitis—worth the risk?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 303-304.	8.2	0

#	ARTICLE	IF	CITATIONS
73	Internal radiation by 131-iodine lipiodol in unresectable hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 962-963.	0.4	0